IgA 신증 : 신규 요법, 미충족 수요 및 TPP 인사이트 보고서(2026년)

IgA Nephropathy Emerging Therapy and TPP Insights

Thelansis's "IgA Nephropathy Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

IgA Nephropathy Overview

IgA Nephropathy is the most common primary glomerulonephritis, caused by mesangial deposition of galactose-deficient IgA1 immune complexes, triggering complement activation and progressive glomerular injury. It presents with recurrent hematuria, persistent microscopic hematuria, or proteinuria. Renal biopsy with immunofluorescence confirms diagnosis; proteinuria at or above 0.5g/day, hypertension, and reduced eGFR define high progression risk. Foundational therapy combines RAS blockade, SGLT2 inhibitors, and blood pressure optimization; targeted-release budesonide and sparsentan provide additional disease modification. Treatment aims to reduce proteinuria below 0.5g/day. Regular eGFR and proteinuria monitoring guides escalation, with timely renal replacement planning in progressive disease.

Key Highlights

• IgAN is a chronic, progressive renal disease with significant long-term ESRD risk
• France kidney biopsy cases expected to grow modestly from 1.5K to 1.57K (0.4% CAGR)

Market Overview

• Germany market projected to grow from $116M to $950M (>20% CAGR)
• Growth driven by emerging targeted therapies addressing underlying disease mechanisms, beyond supportive care

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Keymed Biosciences Co.Ltd
• Novartis Pharmaceuticals
• Biohaven Therapeutics Ltd.
• Jiangsu HengRui Medicine Co., Ltd.
• RemeGen Co., Ltd.
• Chengdu Suncadia Medicine Co., Ltd.
• Guangdong Hengrui Pharmaceutical Co., Ltd
• Beijing Mabworks Biotech Co., Ltd.
• Calliditas Therapeutics AB
• Rigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
• Biocity Biopharmaceutics Co., Ltd.
• HI-Bio, A Biogen Company
• Purespring Therapeutics Limited
• Vera Therapeutics, Inc.
• Visterra, Inc.
• Otsuka Pharmaceutical Development & Commercialization, Inc.
• Alpine Immune Sciences Inc, A Subsidiary of Vertex
• Biogen
• Sinocelltech Ltd.
• Jiangsu Hansoh Pharmaceutical Co., Ltd.
• Travere Therapeutics, Inc.
• Arrowhead Pharmaceuticals
• Haisco Pharmaceutical Group Co., Ltd.
• Suzhou Sanegene Bio Inc.
• ADARx Pharmaceuticals, Inc.
• Apellis Pharmaceuticals, Inc.
• Alexion Pharmaceuticals, Inc.
• Amgen

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc.

2. Competitive Landscape

• Current therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key current therapies - profiles and KOL insights
• Emerging therapies
• Key takeaways
• Dx and Tx journey/algorithm
• Key emerging therapies - profiles and KOL insights

3. Product Attribute Analysis

• Key takeaways
• Scientific attributes
• Commercial attributes
• Product positioning

4. Primary Market Research

• Current treatment landscape
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Current challenges
• Unmet needs
• Emerging therapies
• Key therapies vs. focused patient segment
• Key attributes and benefits
• Futures treatment landscape
• Unmet needs and KOL expectations

5. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

6. Regulatory and Reimbursement Environments (by country and payer insights)

7. Appendix (e.g., bibliography, methodology)